Syed T. Husain, Chairman & CEO, Made Scientific, a cell-therapy CDMO, outlined the company’s expansion plan at its headquarters site in New Jersey.

The company is proceeding with a 12,000 square-foot expansion of the company’s existing GMP manufacturing facility in Princeton, New Jersey. The expansion includes 9,000 square feet of new GMP cleanroom manufacturing space. Once fully operational, the site is expected to enable up to approximately 5,000 additional manufacturing batches per year, further expanding capacity for late-phase and commercial programs. Upcoming milestones in the manufacturing expansion are completion of facility construction and build-out and installation and qualification of manufacturing systems for operational readiness in the fourth quarter of 2026. The company is targeting US Food and Drug Administration (FDA) licensure for commercial manufacturing in the first quarter of 2027.

The expansion further establishes the company’s Princeton headquarters as a Center of Excellence for clinical and commercial supply and will support manufacturing of both personalized (autologous) and off-the-shelf (allogeneic) cell therapies. The expansion will meet FDA and EU Annex 1 compliance standards and include high-throughput and automated manufacturing technologies.

Last August (August 2025), the company opened a new 60,000-square-foot GMP manufacturing facility and headquarters in Princeton. The opening marked the completion of a $12-million initial investment in facility upgrades, equipment, and business system digitalization. With expanded GMP capacity to support late-phase and commercial supply, Made Scientific is committed to helping cell therapy innovators bring such therapies to market.